摘要
培育中成药大品种是中成药企业发展的核心关键,而遴选具有潜力的"种子"产品则是中药大品种培育战略的先决条件。通过从价值和风险多个维度构建评价模型,进行专业化的中成药评价,可以高效、专业、客观的遴选出有大品种培育潜力的"种子"产品。该文探讨从药品命名和处方组成、原料药材安全风险和供给保障、竞争态势、政策目录准入、科技支撑、临床证据与认可等维度构建多元评价指标体系,系统、规范的采集中成药产品说明书、质量标准、政策目录、科技文献、市场竞争、临床应用等多方面的信息,并通过"主观评价指标的客观化,客观化指标的量程化",探讨构建中成药产品价值和风险多维评价模型。基于该模型,可对一批中成药产品集中作出快速、综合的研判分析,并在不同类型、不同领域的产品间形成量化比较。基于该模型评价结果,结合专家综合研判,可高质量的遴选出优质"种子"产品,为下一步大品种培育奠定坚实基础。基于该模型对企业中成药产品的整体梳理,可进一步明晰各产品的外部竞争优势和内部优先层级,为企业优化产品结构、完善产品战略布局提供支撑。
It is the core of the development for Chinese patent medicine enterprises to cultivate large varieties of Chinese patent medicine,and the selection of potential"seed"products is the prerequisite for the cultivation strategy.By constructing the evaluation model from multiple dimensions of value and risk,we can conduct specialized evaluation of Chinese patent medicines to effectively,professionally and objectively select the"seed"products with large variety cultivation potential.In this paper,the establishment of a multidimensional evaluation system would be discussed from the aspects of drug naming and prescription composition,safety risk and supply guarantee of raw materials and medicinal materials,competition situation,access to policy catalogue,scientific and technological support,clinical evidence and recognition,systematical and standardized collection of information on product instructions,quality standards,policy catalogue,scientific and technological literature,market competition and clinical application of Chinese patent medicines.Through the objective evaluation index and the range of objective index,the multi-dimensional evaluation model on values and risks of Chinese patent medicine products was discussed.Based on this model,a batch of Chinese patent medicine products can be quickly and comprehensively analyzed,and quantitative comparison can be formed among different types and fields of products.According to the evaluation results of the model and the comprehensive evaluation of experts,high-quality"seed"products can be selec-ted,laying a solid foundation for the next step of large variety cultivation.With use of this model,we can further clarify the external competitive advantages and internal priority levels of each product,and provide support for enterprises to optimize product structure and improve product strategic layout.
作者
李耿
李振坤
杨洪军
詹志来
李洪梅
唐仕欢
LI Geng;LI Zhen-kun;YANG Hong-jun;ZHAN Zhi-lai;LI Hong-mei;TANG Shi-huan(China-Japan Friendship Hospital,Beijing 100029,China;Beijing Big Brand League Technology Consulting Co.,Ltd.,Beijing 100070,China;Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100070,China;Chinese Medicine Resource Center,China Academy of Chinese Medical Sciences,Beijing 100070,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2021年第5期1284-1292,共9页
China Journal of Chinese Materia Medica
基金
国家重点研发计划项目(2019YFC1708900)
国家中医药管理局项目(GZY-KJS-2018-016-09,GZY-FJS-2018-612)。
关键词
中成药
中药大品种
多维评价
模型
风险控制
Chinese patent medicine
large variety of traditional Chinese medicine
multidimensional evaluation
model
risk control
